Novel monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)

Technical Field

The present invention relates generally to antibodies against CTLA-4 and compositions thereof, and immunotherapy in the treatment of cancer, infections or other human diseases using anti-CTLA-4 antibodies.

Background of the Invention

Cancer immunotherapy has become a hot research area of treating cancer. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is one of the validated targets of immune checkpoints. After T cell activation, CTLA-4 quickly expresses on those T cells, generally within one hour of antigen engagement with TCR. CTLA-4 can inhibit T cell signaling through competition with CD28. CD28 mediates one of well characterized T cell co-stimulatory signal: CD28 binding to its ligands CD80 (B7-1) and CD86 (B7-2) on antigen presenting cells leads to T cell proliferation by inducing production of interleukin-2 and anti-apoptotic factors. Due to much higher affinity binding of CTLA-4 to CD80 and CD86 than that of CD28, CTLA-4 can out-compete with CD28 binding on CD80 and CD86, leading to suppression of T cell activation. In addition to induced expression on activated T cells, CTLA-4 is constitutively expressed on the surface of regulatory T cells (Treg), suggesting that CTLA-4 may be required for contact-mediated suppression and associated with Treg production of immunosuppressive cytokines such as transforming growth factor beta and iterleukin-10.

CTLA-4 blockade can induce tumor regression, demonstrating in a

number of preclinical and clinical studies. Two antibodies against CTLA-4 are in clinical development. Ipilimumab (MDX-010, BMS-734016), a fully human anti-CTLA-4 monoclonal antibody of IgG1-kappa isotype, is an immunomodulatory agent that has been approved as monotherapy for treatment of advanced melanoma. The proposed mechanism of action for Ipilimumab is interference of the interaction of CTLA-4, expressed on a subset of activated T cells, with CD80/CD86 molecules on professional antigen presenting cells. This results in T-cell potentiation due to blockade of the inhibitory modulation of T-cell activation promoted by the CTLA-4 and CD80/CD86 interaction. The resulting T-cell activation, proliferation and lymphocyte infiltration into tumors, leads to tumor cell death. The commercial dosage form is a 5 mg/mL concentrate for solution for infusion. Ipilimumab is also under clinical investigation of other tumor types, including prostate and lung cancers. Another anti-CTLA-4 antibody Tremelimumab was evaluated as monotherapy in melanoma and malignant mesothelioma.

Summary

The present disclosure provides isolated antibodies, in particular monoclonal antibodies or humanized monoclonal antibodies.

In one aspect, the present disclosure refers to an antibody or antigen binding fragment thereof, comprising

a light chain variable region comprising a light chain complementary-determining region 1 (LCDR1) defined by SEQ ID NO: 41, LCDR2 defined by SEQ ID NO: 32, and LCDR3 defined by SEQ ID NO: 22, and

a heavy chain variable region comprising a heavy chain complementary determining region 1 (HCDR1) defined by SEQ ID NO: 36, HCDR2 defined by SEQ ID NO: 28, and HCDR3 defined by SEQ ID NO: 18; and

wherein the antibody or the antigen binding fragment specifically binds to CTLA-4.

In another example, the present disclosure refers to an antibody or an antigen binding-fragment thereof, wherein the antibody or the antigen binding-fragment binds to human, monkey and mouse CTLA-4.

The aforesaid antibody or the antigen binding-fragment inhibits CTLA-4 binding to CD80 or CD86.

In the aforesaid antibody or the antigen binding-fragment, binding

epitope of the antibody or antigen binding-fragment comprises N145 or polysaccharide on N145 of CTLA-4.

In one example, the present disclosure provides an antibody or an antigen binding fragment thereof, wherein the antibody or the antigen binding fragment binds to human, monkey CTLA-4, wherein binding epitope of the antibody or antigen binding-fragment comprises P138 of CTLA-4.

In one example, the present disclosure provides an antibody or an antigen binding fragment thereof, wherein the antibody or the antigen binding-fragment

a) binds to human CTLA-4 with a KD of 4.77E-10 M or less; and
b) binds to mouse CTLA-4 with a KD of 1.39E-09 M or less.

The aforesaid antibody, wherein the antibody or the antigen binding-fragment exhibits at least one of the following properties:

a) binds to human CTLA-4 with a KD of between 4.77E-10 M and 2.08E-10 M and to mouse CTLA-4 with a KD of between 1.39E-09 M and 9.06E-10 M;
b) enhances interleukin-2 release from stimulated PBMCs.
c) does not substantially bind to any protein selected from a group consisting of Factor VIII, FGFR, PD-1, CD22, VEGF, CD3, HER3, OX40, and 4-1BB.

The present disclosure provides an antibody or an antigen binding fragment thereof, comprising an amino acid sequence that is at least 70%, 80%, 90% or 95% homologous to a sequence selected from a group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14, wherein the antibody or the antigen binding-fragment specifically binds to

CTLA-4.

The present disclosure provides an antibody or an antigen binding fragment thereof, comprising an amino acid sequence selected from a group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14,

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4.

In another example, the present disclosure refers to an antibody, or an antigen-binding fragment thereof, comprising:

a) a variable region of a heavy chain having an amino acid sequence that is at least 70%, 80%, 90% or 95% homologous to a sequence selected from a group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, and 7; and

b) a variable region of a light chain having an amino acid sequence that is at least 70%, 80%, 90% or 95% homologous to a sequence selected from a group consisting of SEQ ID NOs: 8, 9, 10, 11, 12, 13, and 14, wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4.

The present disclosure provides an antibody or an antigen binding fragment thereof, comprising:

a) a variable region of a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, and 7; and

b) a variable region of a light chain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 9, 10, 11, 12, 13, and 14,

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4.

In various examples, the antibody or an antigen binding fragment thereof comprises:

a) a variable region of a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 1; and

b) a variable region of a light chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 8,

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4;

or the antibody or an antigen binding fragment thereof comprises:

a) a variable region of a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 2; and

b) a variable region of a light chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 9,

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4;

or the antibody or an antigen binding fragment thereof comprises:

a) a variable region of a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 3; and

b) a variable region of a light chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 10,

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4;

or the antibody or an antigen binding fragment thereof comprises:

a) a variable region of a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 4; and

b) a variable region of a light chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 11, wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4;

or the antibody or an antigen binding fragment thereof comprises:

a) a variable region of a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 5; and

b) a variable region of a light chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 12,

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4;

or the antibody or an antigen binding fragment thereof comprises:

a) a variable region of a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 6; and

b) a variable region of a light chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 13,

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4;

or the antibody or an antigen binding fragment thereof comprises:

a) a variable region of a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 7; and

b) a variable region of a light chain having an amino acid sequence selected from the group consisting of SEQ ID NO: 14,

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4;

The sequence of said antibody is shown in Table 1 and Sequence Listing.

Table 1 Deduced amino acid sequences of the antibodies

Clone ID		SEQ ID NO	Amino acid sequence
W3162-1.101.2	Heavy chain	1	EEQLVESGGGLVQPGKSLKLSCSASGFTFRSSAMHWIRQPPGKGLDWVAFISSGGDTAYADAVKGRFIVSRDNAENTLFLQLNSLKSEDTAIYYCVRMERIPTWGQGVMVTVSS
	Light chain	8	DIVLTQSPVLAVSLGQRATISCRASQSVSISSSINLIHWYQQRPGQQPKLLIYRTSNLASGIPARFSGSGSGTDFTLSIDPVQADDVADYYCQQSRESPLTFGSGTKLEIK
W3162-1.	Heavy chain	2	EVQLVESGGGLVQPGRSLKLSCAASDLTFSNYDMAWVRQTPTKGLEWVASISPNGGNTYYRDSVKGRFTVSRDNAKNSLYLQMDSLRSEDTATYYCARHLWFAYWGQGTLVTVS

145.10			S
	Light chain	9	DIQMTQSPSSMSASLGDRVTISCQASQDIGSNLIWFQQKPGKSPRPMIYYATHLADGVPSRFSGSRSGSDYSLTISSLESEDVADYHCLQYKQYPRTFGGGTKLELK
W3162-1.146.19	Heavychain	3	EVQLQESGPGLVKPSQSLSLTCSVTYHTITSGYDWTWIRKFPGNQMEWMGYISYSGNTNYNPSLKSRISITRDTSKNQFFLHLNSVTSEDTATYYCASMMVPHYYVMDAWGQGASVTVSS
	Light chain	10	DVVLTQTPPTSSATIGQSVSISCRSSQSLLNSDGNTYLYWYLQRPSQSPQLLIYLVSKLGSGVPNRFSGSGSGTDFTLKISGVEAEDLGLYYCVQGTHDPWTFGGGTKLELK
W3162-1.154.8	Heavychain	4	EVQLQQSGPEAGRPGSSVKISCKASGYTFTNYFMNWVKQSPGQGLEWIGRVDPENGRADYAEKFKKKATLTADTTSNTAYIHLSSLTSEDTATYFCARRAMDNYGFAYWGQGTLVTVSS
	Light chain	11	EIMLTQSPTIMAASLGEKITITCSANSSLSYMYWFQQKSGASPKLWVHGTSNLASGVPDRFSGSGSGTSYYLTINTMEAEDAATYFCHHWSNTQWTFGGGTKLELK
W3162-1 .145.10-z7	Heavychain	5	EVQLVESGGGLVQPGGSLRLSCAASDLTFSNYDMAWVRQAPGKGLEWVASISPSGGNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHLWFAYWGQGTLVTVSS
	Light chain	12	DIQMTQSPSSLSASVGDRVTITCQASQDIGSNLIWFQQKPGKAPKPMIYYATHLADGVPSRFSGSRSGTDYTLTISSLQPEDFATYYCLQYKQYPRTFGGGTKVEIK
W3162.1.146.-z12	Heavychain	6	QVQLQESGPGLVKPSETLSLTCSVTYHTITSGYDWTWIRKPPGKGMEWIGYISYSGNTNYNPSLKSRVTISRDTSKNQFFLKLSSVTAADTAVYYCASMMVPHYYVMDAWGQGTLVTVSS
	Light chain	13	DIVMTQTPLSLSVTPGQPASISCRSSQSLLNSDGNTYLYWYLQKPGQSPQLLIYLVSKLGSGVPNRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGTHDPWTFGGGTKVEIK
W3162.1.154.8-z35	Heavychain	7	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYFMNWVRQAPGQGLEWMGRVDPEQGRADYAEKFKKRVTITADKSTSTAYMELSSLRSEDTAVYYCARRAMDNYGFAYWGQGTLVTVSS
	Light chain	14	EIVLTQSPDFQSVTPKEKVTITCSANSALSYMYWYQQKPDQSPKLWVHGTSNLASGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCHHWSNTQWTFGGGTKVEIK

In another example, the disclosure provides an antibody or an antigen binding fragment thereof, comprising a complementarity-determining region (CDR) having an amino acid sequence selected from the group consisting of SEQ ID NOs: 15-41,

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4.

In another example, the disclosure provides an antibody, or an antigen binding fragment thereof, comprising: a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences; and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences,

wherein the heavy chain variable region CDR3 sequence comprises an amino acid sequence selected from a group consisting of SEQ ID NOs: 15, 16, 17, and 18, and conservative modifications thereof,

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4.

Preferably, wherein the light chain variable region CDR3 sequence of the aforesaid antibody or antigen binding fragment thereof comprises an amino acid sequence selected from a group consisting of SEQ ID NOs: 19, 20, 21, and 22, and conservative modifications thereof.

Preferably, wherein the heavy chain variable region CDR2 sequence of the aforesaid antibody or antigen binding fragment thereof comprises an amino acid sequence selected from a group consisting of amino acid sequences of SEQ ID NOs: 23, 24, 25, 26, 27, and 28, and conservative modifications thereof.

Preferably, wherein the light chain variable region CDR2 sequence of the aforesaid antibody or antigen binding fragment thereof comprises an amino acid sequence selected from a group consisting of amino acid sequences of SEQ ID NOs: 29, 30, 31, and 32, and conservative modifications thereof.

Preferably, wherein the heavy chain variable region CDR1 sequence of the aforesaid antibody or antigen binding fragment thereof comprises an amino acid sequence selected from a group consisting of amino acid sequences of SEQ ID NOs: 33, 34, 35, and 36, and conservative modifications thereof.

Preferably, the antibody of this disclosure, wherein the light chain

variable region CDR1 sequence of the aforesaid antibody or antigen binding fragment thereof comprises an amino acid sequence selected from a group consisting of amino acid sequences of SEQ ID NOs: 37, 38, 39, 40, and 41, and conservative modifications thereof.

In more preferred example, the disclosure provides an antibody, or an antigen binding fragment thereof, wherein the antibody or antigen binding fragment specifically binds to CTLA-4 and comprises: a heavy chain variable region that comprises CDR1, CDR2, and CDR3 sequences; and a light chain variable region that comprises CDR1, CDR2, and CDR3 sequences, wherein:

a) the heavy chain variable region CDR1 sequence comprises an amino acid sequence selected from a group consisting of amino acid sequences of SEQ ID NOs: 33, 34, 35, and 36, and CDR2 sequence comprises an amino acid sequence selected from a group consisting of amino acid sequences of SEQ ID NOs: 23, 24, 25, 26, 27, and 28, CDR3 sequence comprises an amino acid sequence selected from a group consisting of amino acid sequences of SEQ ID NOs: 15, 16, 17, and 18;

b) and the light chain variable region CDR1 sequence comprises an amino acid sequence selected from a group consisting of amino acid sequences of SEQ ID NOs: 37, 38, 39, 40, and 41, and CDR2 sequence comprises an amino acid sequence selected from a group consisting of amino acid sequences of SEQ ID NOs: 29, 30, 31, and 32, CDR3 sequence comprises an amino acid sequence selected from a group consisting of amino acid sequences of SEQ ID NOs: 19, 20, 21, and 22,

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4.

A preferred antibody or an antigen binding fragment thereof comprises:

a) a heavy chain variable region CDR1 comprising SEQ ID NO: 15;

b) a heavy chain variable region CDR2 comprising SEQ ID NO: 23;

c) a heavy chain variable region CDR3 comprising SEQ ID NO: 33;

d) a light chain variable region CDR1 comprising SEQ ID NOs: 19;

e) a light chain variable region CDR2 comprising SEQ ID NOs: 29;

f) a light chain variable region CDR3 comprising SEQ ID NOs: 37;

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4.

Another preferred antibody or an antigen binding fragment thereof comprises:

a) a heavy chain variable region CDR1 comprising SEQ ID NO: 16;

b) a heavy chain variable region CDR2 comprising SEQ ID NOs: 24;

c) a heavy chain variable region CDR3 comprising SEQ ID NOs: 34;

d) a light chain variable region CDR1 comprising SEQ ID NOs: 20;

e) a light chain variable region CDR2 comprising SEQ ID NO: 30;

f) a light chain variable region CDR3 comprising SEQ ID NO: 38;

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4.

Another preferred antibody or an antigen binding fragment thereof comprises:

a) a heavy chain variable region CDR1 comprising SEQ ID NO: 17;

b) a heavy chain variable region CDR2 comprising SEQ ID NO: 25;

c) a heavy chain variable region CDR3 comprising SEQ ID NO: 35;

d) a light chain variable region CDR1 comprising SEQ ID NO: 19;

e) a light chain variable region CDR2 comprising SEQ ID NO: 31;

f) a light chain variable region CDR3 comprising SEQ ID NO: 39;

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4.

Another preferred antibody or an antigen binding fragment thereof comprises:

a) a heavy chain variable region CDR1 comprising SEQ ID NO: 18;

b) a heavy chain variable region CDR2 comprising SEQ ID NO: 26;

c) a heavy chain variable region CDR3 comprising SEQ ID NO: 36;

d) a light chain variable region CDR1 comprising SEQ ID NO: 22;

e) a light chain variable region CDR2 comprising SEQ ID NO: 32;

f) a light chain variable region CDR3 comprising SEQ ID NO: 40;

wherein the antibody specifically binds to CTLA-4.

Another preferred antibody or an antigen binding fragment thereof comprises:

a) a heavy chain variable region CDR1 comprising SEQ ID NO: 16;

b) a heavy chain variable region CDR2 comprising SEQ ID NO: 27;

c) a heavy chain variable region CDR3 comprising SEQ ID NO: 34;

d) a light chain variable region CDR1 comprising SEQ ID NO: 20;

e) a light chain variable region CDR2 comprising SEQ ID NO: 30;

f) a light chain variable region CDR3 comprising SEQ ID NO: 38;

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4.

Another preferred antibody or an antigen binding fragment thereof comprises:

a) a heavy chain variable region CDR1 comprising SEQ ID NO: 17;

b) a heavy chain variable region CDR2 comprising SEQ ID NO: 25;

c) a heavy chain variable region CDR3 comprising SEQ ID NO: 35;

d) a light chain variable region CDR1 comprising SEQ ID NO: 21;

e) a light chain variable region CDR2 comprising SEQ ID NO: 31;

f) a light chain variable region CDR3 comprising SEQ ID NO: 39;

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4.

Another preferred antibody or an antigen binding fragment thereof comprises:

a) a heavy chain variable region CDR1 comprising SEQ ID NO: 18;

b) a heavy chain variable region CDR2 comprising SEQ ID NO: 28;

c) a heavy chain variable region CDR3 comprising SEQ ID NO: 36;

d) a light chain variable region CDR1 comprising SEQ ID NO: 22;

e) a light chain variable region CDR2 comprising SEQ ID NO: 32;

f) a light chain variable region CDR3 comprising SEQ ID NO: 41;

wherein the antibody or the antigen binding-fragment specifically binds to CTLA-4.

The CDR sequences of said antibodies are shown in Table 2 and Sequence Listing.

Table 2 The CDR sequences of the antibodies

Clone ID.		SEQ ID NO	CDR1	SEQ ID NO	CDR2	SEQ ID NO	CDR3
W3162-1.101.2	Heavy chain	33	SSAMH	23	FISSGGDTAYADAVKG	15	MERIPT
	Light chain	37	RASQSVSISSINLIH	29	RTSNLAS	19	QQSRESPLT
W3162-1.145.10	Heavy chain	34	NYDMA	24	SISPNGGNTYYRDSVKG	16	HLWFAY
	Light chain	38	QASQDIGSNLI	30	YATHLAD	20	LQYKQYPRT
W3162-1.146.19	Heavy chain	35	SGYDWT	25	YISYSGNTNYNPSLKS	17	MMVPHYYVMDA
	Light chain	39	RSSQSLLNSDGNTYLY	31	LVSKLGS	21	VQGTHDPWT
W3162-1.154.8	Heavy chain	36	NYFMN	26	RVDPENGRADYAEKFKK	18	RAMDNYGFAY
	Light chain	40	SANSSLSYMY	32	GTSNLAS	22	HHWSNTQWT
W3162-1 .145.10-z7	Heavy chain	34	NYDMA	27	SISPSGGNTYYRDSVKG	16	HLWFAY
	Light chain	38	QASQDIGSNLI	30	YATHLAD	20	LQYKQYPRT
W3162.1.146.-z12	Heavy chain	35	SGYDWT	25	YISYSGNTNYNPSLKS	17	MMVPHYYVMDA
	Light chain	39	RSSQSLLNSDGNTYLY	31	LVSKLGS	21	VQGTHDPWT
W3162.1.154.8-z35	Heavy chain	36	NYFMN	28	RVDPEQGRADYAEKFKK	18	RAMDNYGFAY

	Light chain	41	SANSALSY MY	32	GTSNLAS	22	HHWSNTQWT

The antibodies of the disclosure can be chimeric antibody.

The antibodies of the disclosure can be humanized antibody.

The antibodies of the disclosure can be fully human antibody.

The antibodies of the disclosure can be rat antibody.

The antibodies or the antigen binding fragment thereof of the disclosure can exhibit at least one of the following properties:

a) binds to human CTLA-4 with a KD of 2.08E-09 M or less and/or to mouse CTLA-4 with a KD of 1.39E-09 M or less;

b) enhances interleukin-2 release from the stimulated PBMCs;

In a further aspect, the present disclosure refers to a nucleic acid molecule encoding the antibody or the antigen binding fragment thereof as disclosed herein.

The disclosure provides a cloning or expression vector comprising the nucleic acid molecule encoding the antibody, or antigen binding fragment thereof.

In another aspect, the present disclosure refers to a cloning or expression vector comprising the nucleic acid molecule as disclosed herein.

The disclosure also provides a host cell comprising one or more cloning or expression vectors.

In another aspect, the present disclosure refers to a host cell comprising one or more expression vectors as disclosed herein.

In yet another example, the disclosure provides a process, comprising culturing the host cell of the disclosure and isolating the antibody, wherein the antibody is prepared through immunization in a SD rat with human CTLA-4 extracellular domain and mouse CTLA-4 extracellular domain.

In another aspect, the present disclosure refers to a process for the production of the antibody as disclosed herein, comprising culturing the host cell as disclosed herein and isolating the antibody.

The disclosure provides a transgenic animal such as rat comprising human immunoglobulin heavy and light chain transgenes, wherein the rat expresses the antibody of this disclosure.

In another aspect, the present disclosure refers to a transgenic rat comprising human immunoglobulin heavy and light chain transgenes, wherein the rat expresses the antibody as disclosed herein.

The disclosure provides hybridoma prepared from the rat of this disclosure, wherein the hybridoma produces said antibody.

In a further example, the disclosure provides pharmaceutical composition comprising the antibody, or the antigen binding fragment of said antibody in the disclosure, and one or more of a pharmaceutically acceptable excipient, a diluent or a carrier.

In another aspect, the present disclosure refers to a pharmaceutical composition comprising the antibody or the antigen binding fragment thereof as disclosed herein, and one or more of a pharmaceutically acceptable excipient, a diluent and a carrier.

The disclosure provides an immunoconjugate comprising said antibody, or antigen-binding fragment thereof in this disclosure, linked to a therapeutic agent.

In another aspect, the present disclosure refers to an immunoconjugate comprising the antibody or the antigen binding fragment thereof as disclosed herein, linked to a therapeutic agent.

Wherein, the disclosure provides a pharmaceutical composition comprising said immunoconjugate and one or more of a pharmaceutically acceptable excipient, a diluent or a carrier.

In another example, the present disclosure refers to a method for preparing an anti-CTLA-4 antibody or an antigen-binding fragment thereof comprising:

(a) providing:

(i) a heavy chain variable region antibody sequence comprising a CDR1 sequence that is selected from a group consisting of SEQ ID NOs: 33-36, a CDR2 sequence that is selected from a group consisting of SEQ ID NOs: 23-28; and a CDR3 sequence that is selected from the group consisting of SEQ ID NOs: 15-18; and/or

(ii) a light chain variable region antibody sequence comprising a CDR1 sequence that is selected from the group consisting of SEQ ID NOs: 37-41, a

CDR2 sequence that is selected from the group consisting of SEQ ID NOs: 29-32, and a CDR3 sequence that is selected from the group consisting of SEQ ID NOs: 19-22; and

(b) expressing the altered antibody sequence as a protein.

In another aspect, the present disclosure refers to a method for preparing an anti-CTLA-4 antibody or an antigen-binding fragment thereof comprising:

(a) providing:

(i) a heavy chain variable region antibody sequence comprising a CDR1 sequence of SEQ ID NO: 36, a CDR2 sequence of SEQ ID NO: 28; and a CDR3 sequence of SEQ ID NO: 18; and

(ii) a light chain variable region antibody sequence comprising a CDR1 sequence of SEQ ID NO: 41, a CDR2 sequence of SEQ ID NO: 32, and a CDR3 sequence of SEQ ID NO: 22; and

(b) expressing the antibody sequence as a protein.

In another aspect, the present disclosure refers to the antibody or antigen binding fragment thereof as disclosed herein for use as a medicament.

The disclosure also provides a method of modulating an immune response in a subject comprising administering to the subject the antibody, or antigen binding fragment of any one of said antibodies in this disclosure.

In another example, the present disclosure refers to use of the antibody or the antigen binding fragment thereof as disclosed herein in the manufacture of a medicament for the treatment or prophylaxis of an immune disorder or cancer.

In another aspect, the present disclosure refers to use of the antibody or the antigen binding fragment thereof as disclosed herein in the manufacture of a medicament for the treatment of cancer.

The disclosure also provides a method of inhibiting growth of tumor cells in a subject, comprising administering to the subject a therapeutically effective amount of said antibody, or said antigen-binding fragment to inhibit growth of the tumor cells.

In another aspect, the present disclosure refers to use of the antibody or the antigen binding fragment thereof as disclosed herein in the manufacture of a medicament for inhibiting growth of tumor cells.

Wherein, the disclosure provides the method, wherein the tumor cells are of a cancer selected from a group consisting of melanoma, renal cancer, prostate cancer, breast cancer, colon cancer, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, and rectal cancer.

Wherein, the disclosure provides the method, wherein the antibody is a chimeric antibody, humanized antibody, human antibody or rat antibody.

The features and advantages of this disclosure

The inventors have generated humanized antibodies against CTLA-4

utilizing the proprietary hybridoma technology, wherein the antibodies inhibited CTLA-4 binding to its ligands CD80 and CD86. The antibodies reported in this disclosure have high binding affinity, specifically binding to both human and monkey CTLA-4 protein; and potent modulating immune responses and increasing interleukin-2 production.

One of the antibodies not only bound to human and monkey CTLA-4, but also bound to murine CTLA-4, which could greatly facilitate preclinical validation of its efficacy in mouse tumor models.

Brief Description of the Drawings

Figure 1 shows graphs of chimeric antibodies binding to human CTLA-4 in ELISA.

Figure 2 shows graphs of chimeric antibodies binding to cyno CTLA-4 in ELISA.

Figure 3 shows graphs of chimeric antibodies binding to mouse CTLA-4 in ELISA.

Figure 4 shows graphs of chimeric antibodies binding to human CTLA-4 on cells by FACS.

Figure 5 shows the result of chimeric antibodies binding on human CTLA-4 by SPR.

Figure 6 shows the result of chimeric antibodies blocking ligand binding.

Figure 7 shows graphs of chimeric Abs inhibited CTLA-4 binding on CD80- or CD86- expressing cells.

Figure 8 shows the results of chimeric antibodies enhanced cytokine release from SEB stimulated PBMCs.

Figure 9 shows graphs of humanized antibodies binding to human, cynomolgus monkey and mouse CTLA-4 in ELISA.

Figure 10a shows graphs of humanized antibodies binding to CTLA-4 on cells (FACS).

Figure 10b shows graphs of affinity of humanized antibodies by FACS.

Figure 11 shows that humanized antibodies block ligand binding by ELISA.

Figure 12 shows that humanized antibodies block CTLA-4 binding to its ligands by FACS.

Figure 13 shows that humanized antibodies enhance cytokine release in SEB assay.

Figure 14 shows the SEC profile of W3162-1.146.19-Z12 or W3162-1.154.8-Z35 at different conditions.

Figure 15 shows the result of in vivo efficacy of antibody W3162-146.19-z12.

Figure 16 shows that W3162 antibodies specifically bind to CTLA-4.

Figure 17. Binding activity of anti-CTLA4 antibodies with human CTLA-4/CTLA-4 mutants. (A) Ipilimumab, (B) W3162-1.146.19-z12 and (C) W3162-1.154.8-z35 antibodies were captured with pre-coated with 2 μg/ml goat-anti-human-IgG Fc antibody, and then incubated with diluted hCTLA4-His (WT) or its muteins (N113Q and N145Q), then HRP-anti-His antibody was added for detection.

Figure 18 shows the binding residues or epitopes mapped on human CTLA-4: (A) Binding sites of CD80 (PDB:1I8L), (B) CD86 (PDB:1I85), (C) tremelimumab (PDB: 5GGV), (D) Ipilimumab, (E) W3162-1.146.19-z12 and (F) W3162-1.154.8-z35, respectively. The CTLA-4 structure of IAH1 was used for D-F to show the structure of glycosylation.

Detailed description

In order that the present invention may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.

The terms “Cytotoxic T lymphocyte-associated antigen-4”, “Protein CTLA-4”, “CTLA-4”, “CTLA4”, “CD152” are used interchangeably, and include variants, isoforms, species homologs of human CTLA-4 or CTLA-4 of other species, and analogs having at least one common epitope with CTLA-4.

The term “antibody” as referred to herein includes whole antibodies and any antigen- binding fragment (i.e., "antigen-binding portion") or single chains thereof. An "antibody" refers to a protein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, or an antigen-binding portion thereof. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.

The term "antibody," as used in this disclosure, refers to an immunoglobulin or a fragment or a derivative thereof, and encompasses any polypeptide comprising an antigen-binding site, regardless whether it is produced in vitro or in vivo. The term includes, but is not limited to, polyclonal, monoclonal, monospecific, polyspecific, non-specific, humanized, single-chain, chimeric,

synthetic, recombinant, hybrid, mutated, and grafted antibodies. The term "antibody" also includes antibody fragments such as Fab, F(ab')2, Fv, scFv, Fd, dAb, and other antibody fragments that retain antigen-binding function, i.e., the ability to bind CTLA-4 specifically. Typically, such fragments would comprise an antigen-binding fragment.

The terms "antigen-binding fragment," "antigen-binding domain," and "binding fragment" refer to a part of an antibody molecule that comprises amino acids responsible for the specific binding between the antibody and the antigen. In instances, where an antigen is large, the antigen-binding fragment may only bind to a part of the antigen. A portion of the antigen molecule that is responsible for specific interactions with the antigen-binding fragment is referred to as "epitope" or "antigenic determinant."

An antigen-binding fragment typically comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH), however, it does not necessarily have to comprise both. For example, a so-called Fd antibody fragment consists only of a VH domain, but still retains some antigen-binding function of the intact antibody.

In line with the above the term "epitope" defines an antigenic determinant, which is specifically bound/identified by a binding fragment as defined above. The binding fragment may specifically bind to/interact with conformational or continuous epitopes, which are unique for the target structure, e.g. the human CTLA-4 and murine CTLA-4. A conformational or discontinuous epitope is characterized for polypeptide antigens by the presence of two or more discrete amino acid residues which are separated in the primary sequence, but come together on the surface of the molecule when the polypeptide folds into the native protein/antigen. The two or more discrete amino acid residues contributing to the epitope are present on

separate sections of one or more polypeptide chain(s). These residues come together on the surface of the molecule when the polypeptide chain(s) fold(s) into a three-dimensional structure to constitute the epitope. In contrast, a continuous or linear epitope consists of two or more discrete amino acid residues, which are present in a single linear segment of a polypeptide chain.

The term "binds to an epitope of CTLA-4" refers to the antibodies have specific binding for a particular epitope of CTLA-4, which may be defined by a linear amino acid sequence, or by a tertiary, i.e., three-dimensional, conformation on part of the CTLA-4 polypeptide. Binding means that the antibodies affinity for the portion of CTLA-4 is substantially greater than their affinity for other related polypeptides. The term “substantially greater affinity” means that there is a measurable increase in the affinity for the portion of CTLA-4 as compared with the affinity for other related polypeptides. Preferably, the affinity is at least 1.5-fold, 2-fold, 5-fold 10-fold, 100-fold, 10^3-fold, 10^4-fold, 10^5-fold, 10^6-fold or greater for the particular portion of CTLA-4 than for other proteins. Preferably, the binding affinity is determined by enzyme-linked immunoabsorbent assay (ELISA), or by fluorescence-activated cell sorting (FACS) analysis or surface Plasmon resonance (SPR). More preferably, the binding specificity is obtained by fluorescence-activated cell sorting (FACS) analysis.

The term "cross-reactivity" refers to binding of an antigen fragment described herein to the same target molecule in human, monkey, and/or murine (mouse or rat). Thus, "cross-reactivity" is to be understood as an interspecies reactivity to the same molecule X expressed in different species, but not to a molecule other than X. Cross-species specificity of a monoclonal antibody recognizing e.g. human CTLA-4, to monkey, and/or to a murine (mouse or rat) CTLA-4, can be determined, for instance, by FACS analysis.

As used herein, the term "subject" includes any human or nonhuman animal. The term "nonhuman animal" includes all vertebrates, e.g., mammals and non-mammals, such as nonhuman primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc. Except when noted, the terms "patient" or "subject" are used interchangeably.

The terms "treatment" and "therapeutic method" refer to both therapeutic treatment and prophylactic/preventative measures. Those in need of treatment may include individuals already having a particular medical disorder as well as those who may ultimately acquire the disorder.

The terms "conservative modifications" i.e., nucleotide and amino acid sequence modifications which do not significantly affect or alter the binding characteristics of the antibody encoded by the nucleotide sequence or containing the amino acid sequence. Such conservative sequence modifications include nucleotide and amino acid substitutions, additions and deletions. Modifications can be introduced into the sequence by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions include ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

The experimental methods in the following examples are conventional methods, unless otherwise specified.

Examples

Example 1: Research materials preparation

1. Expression and purification of soluble CTLA-4

Human and mouse CTLA-4 extracellular domain (ECD) genes with hexahistidine (6xHis)- or Fc-tag were cloned into expression vector, and then used for transfection of Expi293 cells using Expi293 Expression System Kit. The cells were cultured in Expi293 Expression Medium, on an orbital shaker platform rotating at 135 rpm, in a 37 °C incubator containing a humidified atmosphere with 8% CO_2. The harvested supernatant was used for protein purification. Hexahistidine-tagged proteins were purified using Ni-NTA column and Fc-tagged proteins were purified using Protein A column.

2. Cell lines development

The gene of full length Human CTLA-4 was cloned into an expression vector for development of stable cell line. Briefly, a volume of 30 mL 293F cells at a density of $1x10^6$/mL was transfected with 30 μg DNA using Plasfect Reagent. The transfected cells were put into in an incubator setting at 37 °C, 8% CO_2 and 100 rpm shaking speed. 24-48 hours after transfection, blasticidin at a final concentration of 4-6 μg/mL was used to select the stable clones. The selected clones were tested by FACS using an anti-CTLA-4 antibody.

In order to obtain cells expressing cynomolgus monkey CTLA-4, the gene of full length cynomolgus monkey CTLA-4 was cloned into an expression vector for development of cell pool. Briefly, a volume of 30 mL 293F cells at a density of $1x10^6$/mL was transfected with 30 μg DNA using Plasfect

Reagent (Life Technology). The transfected cells were put into in an incubator setting at 37 °C, 8% CO_2 and 100 rpm shaking speed. 24 hours after transfection, blasticidin at a final concentration of 4 μg/ mL was used to select the cell pool. The selected cell pools were tested by FACS using an anti-CTLA-4 antibody

Example 2: Antibody hybridoma generation

1. Immunization

Human CTLA-4 and murine CTLA-4 were used for immunization of SD rats. Specifically, three SD rats were immunized with 30 μg/animal of human and mouse CTLA-4 ECD protein in adjuvant. The adjuvant included Titer-Max, Adju-Phos and CpG-ODN. The rats were injected once a week both from footpad and subcutaneously. The antibody titer in serum was measured by ELISA every one month. When the antibody titer was sufficiently high, the rat with the highest titer was given a final boost with human and mouse CTLA-4 ECD protein in Dulbecco's Phosphate Buffered Saline (DPBS) without adjuvant. After several days, the spleen and lymph nodes were taken from the rat, and lymphocytes were separated for fusion.

2. Cell fusion

The cell fusion was performed as following: myeloma cells SP2/0 cells were thawed the week before the fusion, and were split at 1:2 every day until the day before the fusion to keep them in logarithmic growth. B lymphocytes isolated from lymph node of immunized rat and myeloma cells were respectively treated with trypsin and the reaction was stopped by adding FBS. B lymphocytes were combined with myeloma cells at 1 : 1 ratio. The cell mixture was then washed and re-suspended at 2×10^6 cells/ml in electric fusion solution containing 0.3 M sucrose, 0.1 mM magnesium acetate and 0.1mM calcium acetate. The electric cell fusion was conducted using Btx Electro Cell Manipulator (Ecm 2001) following the manufacturer's standard

protocol. Then the cell suspension from the fusion chamber was immediately transferred into a sterile flask containing fresh medium, and incubated for 2 hours in 37 °C incubator. The cell suspension was then mixed and transferred into 60 of 96-well plates (1×10^4 cells/well). The 96-well plates were cultured at 37 °C and 5% CO_2 with periodically monitoring. When the clones were big enough (after 7-10 days), 180 μL /well of supernatant were removed and then 200 μL fresh medium per well was add. After 72 hours, 100 μL of supernatant were transferred from the tissue culture plates to 96-well assay plates for screening.

3. Hybridoma screening

A large number of hybridoma clones were screened on binding to human, murine and monkey CTLA-4 proteins as well as engineered human CTLA-4 expressing cells. Once specific CTLA-4 binding and blocking activity were verified through first and second screening, the positive hybridoma lines were subcloned into 96-well plates using limited dilution. The plates were cultured at 37 °C, 5% CO_2 until the positive clones were further screened for competition with ligands CD80 and CD86 binding to CTLA-4. The cultural supernatants of selected positive clones were collected for antibodies purification and further characterization. The lead candidates were selected for VH and VL sequencing.

4. Determination of VH and VL sequences from hybridoma

The VH and VL genes of the antibodies of selected hybridoma clones were isolated by RT-PCR or 5' RACE. Specifically, total RNA was isolated from hybridoma cells by using RNeasy Plus Mini Kit (Qiagen). The first strand cDNA was reverse transcripted using oligo dT. VH and VL genes of the antibodies were amplified from cDNA using 3'- constant region degenerated primer and 5'- degenerated primer sets. The 5' degenerated primers were designed based on the upstream signal sequence-coding region of Ig variable

sequences. The PCR product was then ligated into pMD18-T vector and 10 μL of the ligation product was transformed into Top10 competent cells. Transformed cells were plated on 2xYT plates with carbenicillin and incubated overnight at 37 °C. 15 positive colonies were randomly picked for DNA sequencing by Biosune. Alternatively, 5' RACE was used to identify the VH and VL sequences of selected hybridoma clones. First, RNA was first reverse transcribed into cDNA using 5'-RACE kit (Takara-28001488), followed by PCR using 3'-degenerated primers and 3'-adaptor primers (ExTaq: Takara-RR001B). PCR fragments was inserted into pMD18-T vector (Takara-D101C) and sent for sequencing (Biosune, Shanghai).

Example 3: Chimeric antibodies production and characterization

1. Chimeric antibody production

The deduced amino acid sequences of VH and VL are listed in the Table 3. Underlined sequences are CDRs defined by Kabat delineation system. The variable regions of these rat antibodies were fused with constant region of human antibody, and the chimeric antibodies were expressed from Expi293 cells and purified using Protein A chromatography.

Table 3. The variable region sequence of rat anti-CTLA-4 antibodies

Clone ID		SEQ ID NO	Amino acid sequence
W3162-1.101.2	VH	1	EEQLVESGGGLVQPGKSLKLSCSASGFTFR**SSAMH**WIRQPPGKGLDWVA**FISSGGDTAYADAVKG**RFIVSRDNAENTLFLQLNSLKSEDTAIYYCVR**MERIPT**WGQGVMVTVSS
	VL	8	DIVLTQSPVLAVSLGQRATISC**RASQSVSISSINLIH**WYQQRPGQQPKLLIY**RTSNLAS**GIPARFSGSGSGTDFTLSIDPVQADDVADYYC**QQSRESPLT**FGSGTKLEIK
W3162-1.145.10	VH	2	EVQLVESGGGLVQPGRSLKLSCAASDLTFS**NYDMA**WVRQTPTKGLEWVA**SISPNGGNTYYRDSVKG**RFTVSRDNAKNSLYLQMDSLRSEDTATYYCAR**HLWFAY**WGQGTLVTVSS
	VL	9	DIQMTQSPSSMSASLGDRVTISC**QASQDIGSNLI**WFQQKPGKSPRPMIY**YATHLAD**GVPSRFSGSRSGSDYSLTISSLESEDVADYHC**LQYKQYPRT**FGGGTKLELK

W3162-1.146.19	VH	3	EVQLQESGPGLVKPSQSLSLTCSVTYHTIT**SGYDWT**WIRKFPGNQMEWMG**YISYSGNTNYNPSLKS**RISITRDTSKNQFFLHLNSVTSEDTATYYCAS**MMVPHYYVMDA**WGQGASVTVSS
	VL	10	DVVLTQTPPTSSATIGQSVSISC**RSSQSLLNSDGNTYLY**WYLQRPSQSPQLLIY**LVSKLGS**GVPNRFSGSGSGTDFTLKISGVEAEDLGLYYC**VQGTHDPWT**FGGGTKLELK
W3162-1.154.8	VH	4	EVQLQQSGPEAGRPGSSVKISCKASGYTFT**NYFMN**WVKQSPGQGLEWIG**RVDPENGRADYAEKFKK**KATLTADTTSNTAYIHLSSLTSEDTATYFCAR**RAMDNYGFAY**WGQGTLVTVSS
	VL	11	EIMLTQSPTIMAASLGEKITITC**SANSSLSYMY**WFQQKSGASPKLWVH**GTSNLAS**GVPDRFSGSGSGTSYYLTINTMEAEDAATYFC**HHWSNTQWT**FGGGTKLELK

2. Characterization of chimeric antibodies

2.1 Antibodies bound to human, monkey and murine CTLA-4 (ELISA, FACS and SPR)

Chimeric antibodies with rat variable region and human constant region were expressed from mammalian cells and purified using Protein A affinity chromatography.

The antibodies were tested on CTLA-4-binding ELISA. As shown in Figure 1, 2 and 3, all the four antibodies bound to human and monkey CTLA-4 with EC50 comparable to Ipilimumab (WBP316-BMK1), but only one antibody W3162-1.146.19 also bound to murine CTLA-4 at EC_{50} of 0.01 nM. In order to confirm that the antibodies were able to bind CTLA-4 on cell surface, a CTLA-4- expressing cell line was used in FACS assays. These antibodies also bound to CTLA-4 on cell surface (Figure 4) with EC_{50} ranging from 1.14 nM to 9.42 nM. W3162-1.146.19 bounds to CTLA-4 on cell surface with EC_{50} of 3.25 nM and W3162-1.154.8 bounds to CTLA-4 on cell surface with EC_{50} of 1.26 nM.

The binding kinetics of four antibodies were measured using SPR. The antibodies were captured on immobilized goat anti-human Fc, and then human CTLA-4 ECD at different concentration was injected orderly. The

sensorgrams for reference channel and buffer channel were subtracted from the test sensorgrams. The data was used to fit in 1:1 binding analysis. As show in the Figure 5 and Table 4, all the four antibodies bound to human CTLA-4 ECD domain with higher affinity than Ipilimumab (WBP316-BMK1), with K_D range of 2.08 E-09 nM to 6.80E-11 nM.

Table 4. Kinetic of antibody binding on human CTLA-4 ECD

Antibody	ka (1/Ms)	kd (1/s)	K_D (M)
W3162-1.101.2 xAb.IgG1	6.95E+05	6.97E-05	**1.00E-10**
W3162-1.145.10 xAb.IgG1	7.93E+06	1.65E-02	**2.08E-09**
W3162-1.146.19 xAb.IgG1	7.09E+05	1.48E-04	**2.08E-10**
W3162-1.154.8 xAb.IgG1	1.85E+06	1.25E-04	**6.80E-11**
WBP316-BMK1	9.42E+05	3.46E-03	**3.68E-09**

2.2 Competition with ligands of chimeric antibodies

CTLA-4 was found binding to both CD80 and CD86 at 20 to 50 folds higher affinity than CD28 [Krummel 1996]. Therefore, the anti-CTLA-4 antibodies were tested whether they can compete with CD80 and CD86's binding on CTLA-4. Both ELISA and FACS were used as the competition assays. In ELISA based competition assay, human CTLA-4 was coated on the plates, and the antibodies mixed with biotinylated ligands were added into the plate. The bound ligands were detected by HRP conjugated streptavidin. As shown in Figure 6a and 6b, all four antibodies competed with ligands CD80 (B7-1, L1) and CD86 (B7-2, L2) in CTLA-4 binding, and three of them except W3162-1.101.2 had comparable EC_{50} with Ipilimumab (WBP316-BMK1). In a FACS assay, the mixture of antibodies and biotinylated human CTLA-4 was added to CD80 or CD86 expressing cells, and the bound human CTLA-4 was detected by PE conjugated streptavidin. As shown in Figure 7a (upper panel) and 7b (lower panel), all the four antibodies could effectively block CTLA-4's binding on the

ligand-expressing cells. Three antibodies except W3162-1.154.8 could completely block CTLA-4 binding on CD80 cells, whereas Ipilimumab WBP316-BMK could only partially block this binding even at 200 nM, the highest concentration used (Figure 7a). In the FACS assay of blocking CTLA-4 binding on CD86 cells (Figure 7b), All of 4 antibodies could completely block CTLA-4 binding on CD86 cells, whereas Ipilimumab could only partially block this binding even at 200 nM, the highest concentration used. The kinetics of W3162-1.101.2 appeared differently: the blocking was less effective than Ipilimumab at low concentration and more effective than Ipilimumab at high concentration. Other three antibodies were more effective than Ipilimumab in blocking CTLA-4 at all the concentration tested.

2.3 Function in SEB assay of chimeric antibodies

The function of anti-CTLA-4 antibodies with different concentration of 1.34 nM, 3.35 nM, 8.71 nM, 21.4 nM, 53.6 nM, 134 nM were tested in a modified T cell stimulation assay (SEB assay). Staphylococcal enterotoxin B (SEB) was used as a stimulator of human T cell activation, in which CTLA-4 was reported as an important player. The T cell activation was measured by secretion of IL-2. As shown in the Figure 8, all the four antibodies promoted IL-2 secretion in a dose dependent manner, comparable with or superior to Ipilimumab.

Example 4: Characterization of humanized antibody

1. Humanization

"Best Fit" approach was used to humanize antibody light and heavy chains.

Three anti-CTLA-4 antibodies (except W3162-1.101.2 due to its relatively low binding activity in ELISA and FACS) were selected for humanization, using CDR-grafting technique. The CDRs (underlined in Table 5) and FRs of variable regions of the antibodies were defined using Kabat system. Based on

the sequence homology and structural similarity, the gene of rat region FR1-3 was replaced by humanized region FR1-3, while region FR4 of the rat gene was replaced by humanized FR4 region derived from JH and JK genes that had the most similar structures. The hot spots of post-translational modification (PTM) of variable regions were modified to reduce the PTM risk. After verifying the template sequence and codon optimization, the heavy chain variable region and light chain variable region were synthesized and cloned into an expression vector, and then used for expression of the humanized antibodies. The humanized antibodies were purified using Protein A chromatography, and the kinetics binding on human, monkey and murine CTLA-4 were measured using SPR method.

Table 5. The variable region sequence of humanized anti-CTLA-4 antibodies

Clone ID		SEQ ID NO	Amino acid sequence
W3162-1 .1 45.10-z7	VH	5	EVQLVESGGGLVQPGGSLRLSCAASDLTFSNYDMAWVRQAPG KGLEWVASISPSGGNTYYRDSVKGRFTISRDNAKNSLYLQMNS LRAEDTAVYYCARHLWFAYWGQGTLVTVSS
	VL	12	DIQMTQSPSSLSASVGDRVTITCQASQDIGSNLIWFQQKPGKAP KPMIYYATHLADGVPSRFSGSRSGTDYTLTISSLQPEDFATYYCL QYKQYPRTFGGGTKVEIK
W3162.1.14 6.19-z12	VH	6	QVQLQESGPGLVKPSETLSLTCSVTYHTITSGYDWTWIRKPPGK GMEWIGYISYSGNTNYNPSLKSRVTISRDTSKNQFFLKLSSVTA ADTAVYYCASMMVPHYYVMDAWGQGTLVTVSS
	VL	13	DIVMTQTPLSLSVTPGQPASISCRSSQSLLNSDGNTYLYWYLQK PGQSPQLLIYLVSKLGSGVPNRFSGSGSGTDFTLKISRVEAEDVG VYYCVQGTHDPWTFGGGTKVEIK
W3162.1.15 4.8-z35	VH	7	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYFMNWVRQAP GQGLEWMGRVDPEQGRADYAEKFKKRVTITADKSTSTAYMEL SSLRSEDTAVYYCARRAMDNYGFAYWGQGTLVTVSS
	VL	14	EIVLTQSPDFQSVTPKEKVTITCSANSALSYMYWYQQKPDQSP KLWVHGTSNLASGVPSRFSGSGSGTDFTLTINSLEAEDAATYYC HHWSNTQWTFGGGTKVEIK

Table 6. The variable region of humanized anti-CTLA-4 antibodies

Clone ID		SEQ ID NO	DNA sequence
W3162-1.145.10-z7	VH	42	GAGGTGCAGCTGGTGGAGAGCGGCGGAGGACTGGTGCAACCTGGCGGAAGC CTGAGACTGAGCTGCGCCGCCAGCGACCTGACCTTCAGCAACTACGACATGG CCTGGGTGAGACAGGCCCCTGGCAAGGGACTGGAGTGGGTGGCCAGCATCA GCCCCAGCGGCGGCAACACCTACTACAGGGACAGCGTGAAGGGCAGGTTCA CCATCAGCAGGGACAACGCCAAGAACAGCCTGTACCTGCAGATGAACAGCCT GAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGCACCTGTGGTTCGCC TACTGGGGCCAGGGCACACTGGTGACCGTGAGCAGC
	VL	45	GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGCGATA GGGTGACCATCACCTGCCAGGCCAGCCAGGACATCGGCAGCAACCTGATCTG GTTCCAGCAGAAGCCCGGCAAGGCCCCCAAGCCTATGATCTACTACGCCACCC ACCTGGCCGATGGCGTGCCTAGCAGATTCAGCGGCAGCAGAAGCGGCACCGA CTACACCCTGACCATCAGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACT GCCTGCAGTACAAGCAGTACCCCAGAACCTTCGGCGGCGGCACCAAGGTGGA GATCAAG
W3162-1.146.19-z12	VH	43	CAGGTGCAGCTGCAGGAGAGCGGACCCGGACTGGTGAAGCCCTCCGAGACC CTGAGCCTGACCTGCAGCGTGACCTACCACACCATCACCAGCGGCTACGACT GGACCTGGATCAGAAAGCCCCCCGGCAAAGGCATGGAGTGGATCGGCTACAT CAGCTACAGCGGCAACACCAACTACAACCCCAGCCTGAAGAGCAGGGTGAC CATCAGCAGGGACACCAGCAAGAACCAGTTCTTCCTGAAGCTGAGCAGCGTG ACAGCCGCCGATACCGCCGTGTACTACTGCGCCAGCATGATGGTGCCCCACTA CTACGTGATGGACGCCTGGGGACAGGGCACCCTGGTGACAGTGAGCAGC
	VL	46	GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGC CCGCCAGCATCAGCTGCAGGTCCAGCCAGAGCCTGCTGAACAGCGACGGCAA CACCTACCTGTACTGGTACCTGCAGAAGCCTGGCCAGAGCCCCCAGCTGCTGA TCTACCTGGTGTCCAAGCTGGGCAGCGGCGTGCCTAACAGGTTTAGCGGCAG CGGCAGCGGCACCGATTTCACCCTGAAGATCAGCAGGGTGGAGGCCGAGGAT GTGGGCGTGTACTACTGCGTGCAGGGCACCCACGATCCTTGGACCTTCGGCG GCGGAACCAAGGTGGAGATCAAG
W3162-1.154.8-z35	VH	44	CAGGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCCGGCAGCAGC GTGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTTCATGA ACTGGGTGAGGCAGGCCCCTGGACAAGGCCTGGAGTGGATGGGCAGAGTGG ATCCCGAGCAGGGCAGGGCCGACTACGCCGAGAAGTTCAAGAAGAGGGTGA CCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAGCTGAGCAGCCT GAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGAGAGCCATGGACAA CTACGGCTTCGCCTACTGGGGCCAGGGAACCCTGGTGACCGTGAGCAGC
	VL	47	GAGATCGTGCTGACCCAGAGCCCCGACTTCCAGAGCGTGACCCCCAAGGAGA AGGTGACCATCACCTGCAGCGCCAACAGCGCCCTGAGCTACATGTACTGGTAC CAGCAGAAGCCCGACCAGAGCCCCAAGCTGTGGGTGCACGGCACCAGCAAT CTGGCCAGCGGCGTGCCTAGCAGATTTAGCGGCAGCGGCAGCGGCACCGATT TCACCCTGACCATCAACAGCCTGGAGGCCGAGGACGCCGCTACCTACTACTG CCACCACTGGAGCAACACCCAGTGGACCTTCGGCGGCGGCACCAAGGTGGA GATCAAG

2. Characterization of humanized antibodies

2.1 Antibodies bound to human, monkey and murine CTLA-4

2.1.1 CTLA-4-Binding ELISA

Humanized antibodies were expressed from mammalian cells and purified using Protein A affinity chromatography. Ipilimumab was from commercial

source. Isotype control antibody, human CTLA-4 ECD with different tags (hFc or 6xHis) and murine CTLA-4.ECD-hFc were prepared by WuXi Biologics. Murine CTLA-4.ECD-6xHis and cynomolgus monkey CTLA-4 ECD-6xHis were purchased from Sino Biological. HRP-conjugated goat anti-human IgG Fc was purchased from Bethyl (Cat: A80-304P).

ELISA was used to test binding of anti-human CTLA-4 antibodies to human, murine and cynomolgus monkey CTLA-4 protein. A 96-well plate was coated with human CTLA-4.ECD-6xHis (1.0 μg/mL), cynomoguls monkey CTLA-4.ECD-6xHis (0.5 μg/mL) or mouse CTLA-4.ECD-6xHis (0.5 μg/mL) at 4 °C for 16-20 hours. After 1 hour blocking with 2% BSA in DBPS, testing antibodies, as well as positive and negative control antibodies were added to the plates and incubated at room temperature for 1 hour. The binding of the antibodies to the plates were detected by HRP-conjugated goat anti-human IgG antibody (1:5000 dilution) with 1 hour incubation. The color was developed by dispensing 100 μL of TMB substrate for 8 mins, and then stopped by 100 μL of 2N HCl. The absorbance at 450 nM was measured using a microplate spectrophotometer.

As shown in Figure 9, the two antibodies W3162-1.146.19-z12-IgGk and W3162-1.154.8-z35-IgGk bound to human CTLA-4 with EC_{50} of 0.03 nM and 0.04 nM, respectively, slightly higher than EC_{50} of Ipilimumab (WBP316-BMK1) 0.01 nM (Figure 9A). The two antibodies also bound to monkey CTLA-4 with EC50 of 0.05 nM (Figure 9B), but only W3162-1.146.19-z12-IgGk bound to murine CTLA-4 with EC50 0.19 nM. Neither W3162-1.154.8-z35-IgGk nor Ipilimumab bound to murine CTLA-4 (Figure 9C).

2.1.2 CTLA-4-binding FACS

Human CTLA4 expression 293F cell line was developed by WuXi Biologics.

PE conjugated goat anti-human IgG Fc fragment was purchased from Jackson (Catalog number 109-115-098). A number of 1 x 10^5 cells per well was added to each well of a 96-well plate and centrifuged at 1500 rpm for 4 minutes at 4 °C before removing the supernatant. Serial dilutions of test antibodies, positive and negative controls were added to the resuspended cells and incubated for 1 hour at 4 °C. The cells were washed two times with 200 μL DPBS containing 1% BSA. PE conjugated goat anti-human IgG (1:100) diluted in DPBS containing 1% BSA was added to the cells and incubated at 4 °C for 1 hour. Additional washing steps were performed two times with 200 μL DPBS containing 1% BSA followed by centrifugation at 1500 rpm for 4 minutes at 4 °C. Finally, the cells were resuspended in 100 μL DPBS containing 1% BSA and fluorescence values were measured by flow cytometry and analyzed by FlowJo.

These antibodies were also able to bound human CTLA-4 on cell surface in FACS assay. As shown in Figure 11 (Figure 10a and Figure 10b), W3162-1.146.19-z12-IgGk, W3162-1.154.8-z35-IgGk and Ipilimumab had slightly different EC_{50} of 1.58 nM, 0.66 nM and 0.83 nM, respectively.

2.2 The binding kinetics of these antibodies

2.2.1 The binding kinetics of these antibodies were measured using SPR

The experiment was to measure the on-rate constant (ka) and off-rate constant (kd) of the antibodies to CTLA-4 ECD based on SPR technology. The affinity constant (K_D) was consequently determined.

Biacore T200, Series S Sensor Chip CM5, Amine Coupling Kit, and 10× HBS-EP were purchased from GE Healthcare. Goat anti-human IgG Fc antibody was purchased from Jackson ImmunoResearch Lab (catalog number 109-005-098). In immobilization step, the activation buffer was prepared by mixing 400 mM EDC and 100 mM NHS immediately prior to

injection. The CM5 sensor chip was activated for 420 s with the activation buffer. 30 μg/mL of goat anti-human IgG Fcγ antibody in 10 mM NaAc (pH 4.5) was then injected to Fc1-Fc4 channels for 200s at a flow rate of 5 μL/min. The chip was deactivated by 1 M ethanolamine-HCl (GE). Then the antibodies were captured on the chip. Briefly, 4 μg/mL antibodies in running buffer (HBS-EP+) was injected individually to Fc3 channel for 30 s at a flow rate of 10 μL/min. Eight different concentrations (20 nM, 10 nM, 5 nM, 2.5 nM, 1.25 nM, 0.625 nM, 0.3125 nM and 0.15625 nM) of analyte CTLA-4 (WBP316.hCTLA-4.ECD-6xHis) and blank running buffer were injected orderly to Fc1-Fc4 channels at a flow rate of 30 μL/min for an association phase of 120 s, followed by 2400 s dissociation phase. Regeneration buffer (10 mM Glycine pH 1.5) was injected at 10 μL/ min for 30 s following every dissociation phase.

The binding kinetics of these antibodies were measured using SPR. The antibodies were captured on immobilized anti-human Fc and CTLA-4-ECD at different concentration was injected orderly. The sensorgrams for reference channel and buffer channel were subtracted from the test sensorgrams. The data was used for 1:1 binding analysis on human, monkey and mouse CTLA-4.ECD-6xHis. As show in Table 7, humanized antibodies W3162-1.146.19-Z12, W145 and W3162-1.154.8-Z35 bound to human CTLA-4-ECD domain with affinity at 0.477 nM, 1.84 nM and 0.0968 nM, respectively. Comparing with rat antibodies, the humanized antibodies had comparable affinity. W3162-1.146.19-Z12 and W3162-1.154.8-Z35 have significantly higher affinity than Ipilimumab (K_D=3.68 nM). The antibody W3162-1.146.19-Z12 could also bind to murine CTLA-4, and its affinity before and after humanization is shown in Table 9. After humanization, its affinity 1.39 nM is slightly lower than affinity 0.906 nM of its parental antibody.

The affinity of W3162-1.146.19-Z12, W3162-1.145.10-z7 and W3162-1.154.8-Z35 binding to cynomolgus monkey CTLA-4-ECD was 1.92 nM, 0.598 nM, 0.131 nM, respectively (Table 8).

Table 7. Kinetic of antibody-binding on human CTLA-4 ECD

Antibodies	**ka (1/Ms)**	**kd (1/s)**	**K_D (M)**
W3162-1.146.19-z12-uAb.IgG1K	2.06E+05	9.82E-05	4.77E-10
W3162-1.146.19 xAb.IgG1	7.09E+05	1.48E-04	2.08E-10
W3162_1.145.10-z7-uAb.IgG1K	7.37E+06	1.35E-02	1.84E-09
W3162-1.145.10 xAb.IgG1	7.93E+06	1.65E-02	2.08E-09
W3162_1.154.8-z35-uAb.IgG1K	1.23E+06	1.19E-04	9.68E-11
W3162-1.154.8 xAb.IgG1	1.85E+06	1.25E-04	6.80E-11
Ipilimumab	9.42E+05	3.46E-03	3.68E-09

Table 8. Kinetic of antibody-binding on monkey CTLA-4 ECD

Antibodies	**ka (1/Ms)**	**kd (1/s)**	**K_D (M)**
W3162-1.146.19-z12-uAb.IgG1K	1.73E+05	3.31E-04	1.92E-09
W3162-1.146.19 xAb.IgG1	2.91E+05	1.07E-04	3.69E-10
W3162_1.145.10-z7-uAb.IgG1K	4.52E+06	2.71E-03	5.98E-10
W3162-1.145.10 xAb.IgG1	1.06E+07	3.77E-03	3.55E-10
W3162_1.154.8-z35-uAb.IgG1K	9.32E+05	1.22E-04	1.31E-10
W3162-1.154.8 xAb.IgG1	1.25E+06	1.09E-04	8.72E-11

Table 9. Kinetic of antibody-binding on mouse CTLA-4 ECD

Antibodies	**ka (1/Ms)**	**kd (1/s)**	**K_D (M)**
W3162-1.146.19-z8-uAb.IgG1K	1.72E+05	2.39E-04	1.39E-09
W3162-1.146.19 xAb.IgG1	2.51E+05	2.28E-04	9.06E-10

2.2.2 Affinity test by FACS

FITC conjugated goat anti-human IgG Fc was purchased from Jackson Immunoresearch Lab (catalog number 109-095-098), and BD CantoII was used for this assay. Briefly, HEK293 cells expressing human CTLA-4 were transferred in to 96-well U-bottom plates (BD) at a density of $5x10^4$ cells/well. Testing antibodies were 1:2-fold serially diluted in PBS with 1%BSA and incubated with cells at 4 °C for 1 hour. After centrifugation at 1500 rpm for 4 min, the supernatant was discarded. The secondary antibody,

FITC conjugated goat anti-human IgG Fc (3.2 FITC per IgG, Jackson Immunoresearch Lab), was added to re-suspend cells to final concentration 14 μg/ml, and incubated at 4 °C in the dark for 30 min. The cells were then washed once and re-suspended in PBS with 1%BSA, and analyzed by flow cytometery (BD). Fluorescence intensity was converted to bound molecules/cell based on the quantitative beads (QuantumTM MESF Kits, Bangs Laboratories). K_D was calculated using Graphpad Prism5.

The affinity of humanized antibodies binding to cell surface CTLA-4 was measured by flow cytometry method, modified from Benedict's method [Benedict 1997 JIM]. After measure fluoresce of antibodies binding to CTLA-4-expressing CHO cells, the bound antibody and free antibody were analyzed and fitted to the equation, as shown in Figure 5. Based on the data and formula, calculated affinity constant K_D is shown in the Table 10. Affinity of humanized antibody W3162-1.146.19-Z12 and W3162-1.154.8-Z35 had high affinity at 5.05 and 0.35 nM, respectively, whereas the affinity of Ipilimumab is 0.97 nM.

Table 10. Affinity test by FACS

Sample	K_D (M)	Bmax	R^2
W3162-1.146.19-z12-IgG1K	5.0E-09	1.2E-10	0.99
W3162-1.154.8-z35-IgG1K	3.5E-10	1.2E-10	0.98
Ipilimumab	9.7E-10	7.2E-11	0.99

2.3 Competition with ligands

In order to test whether the humanized antibodies maintained its ability of blocking CTLA-4 binding on CD80 and CD86, both ELISA and FACS were used in competition assay. Two CTLA-4 ligands CD80 and CD86 were purchased from Sino Biological (Catalog number 10698-H08H and 10699-H08H). Biotinylated anti-His tag antibody was purchased from Genscript (Catalog number A00613). HRP conjugated streptavidin was

purchased from Invitrogen (Catalog number SNN1004).

2.3.1 The ELISA-based competition assay

ELISA was used to test whether the antibodies could inhibit the binding of human CTLA-4 to its ligands human CD80 and CD86. Plates were coated with human CTLA-4.ECD.hFc (0.5 μg/mL) at 4 °C for 16-20 hours. After 1 hour blocking with 2% BSA in DBPS, testing antibodies, as well as positive and negative control antibodies were pre-mixed with 0.25 μg/mL of CD80-6xHis or CD86-6xHis, and then added to the plates and incubated at room temperature for 1 hour. After washing three times with PBS containing 0.05% Tween 20, biotinylated anti-His tag antibody was 1:2000 diluted and added. The plates were incubated at room temperature for 1 hour. The bound ligands were detected by HRP conjugated streptavidin (1:20000). The color was developed by dispensing 100 μL of TMB substrate for 8 mins, and then stopped by 100 μL of 2N HCl. The absorbance at 450 nM was measured using a microplate spectrophotometer.

As shown in Figure 11, W3162-1.146.19-z12-IgGk and W3162-1.154.8-z35-IgGk had similar effect as Ipilimumab in blocking ligands binding with coated CTLA-4, with IC_{50} of 0.87 nM, 0.63 nM and 0.40 nM for CD80, and 0.71nM, 0.50 nM and 0.42 nM for CD86.

2.3.2 The FACS assay

To test whether the antibodies could block CTLA-4 binding to CD80 and CD86 on cell surface, we used FACS to test this competition. The CD80- and CD86- expressing CHO cell lines were developed by WuXi Biologics. Biotinylated CTLA-4.ECD.hFc was made by WuXi Biologics. PE conjugated Streptavidin was purchased from eBioscience (Catalog number 12-4317).

CD80- or CD86-expressing cells were added to each well of a 96-well plate at 1×10^5 per well and centrifuged at 1500 rpm for 4 minutes at 4 °C before removing the supernatant. Serial dilutions of test antibodies, positive and negative controls were mixed with biotinylated human CTLA4.ECD.hFc. Due to different density of ligands on cell surface, 0.02 μg/mL of hCTLA-4.ECD.hFc-Biotin was used for human CD80 cells and 0.08 μg/mL of hCTLA-4.ECD.hFc-Biotin for human CD86 cells. Then the mixtures of antibody and CTLA-4 were added to the cells and incubated for 1 hour at 4 °C. The cells were washed two times with 200 μL FACS buffer (DPBS containing 1% BSA). Streptavidin PE 1 to 333 diluted in FACS buffer was added to the cells and incubated at 4 °C for 1 hour. Additional washing steps were performed two times with 200 μL FACS buffer followed by centrifugation at 1500 rpm for 4 minutes at 4 °C. Finally, the cells were resuspended in 100 μL FACS buffer and fluorescence values were measured by flow cytometry and analyzed by FlowJo.

The results are shown in Figure 12. The two humanized antibodies could more effectively block CTLA-4/ligand binding than Ipilimumab. At the highest concentration used, Ipilimumab only blocked 32% CTLA-4 binding to CD80 and 40% of CTLA-4 binding to CD86. In comparison, antibody W3162-1.146.19-Z12 blocked 71% of CTLA-4 binding on CD80 and 73% of CTLA-4 binding on CD86, and antibody W3162-1.154.8-Z35 blocked 89% of CTLA-4 binding on CD80 and 98% of CTLA-4 binding on CD86. IC_{50} of Ipilimumab, W3162-1.146.19-Z12 and W3162-1.154.8-Z35 directing against CD80 were 3.23, 6.60 and 0.07 nM respectively. IC_{50} of Ipilimumab, W3162-1.146.19-Z12 and W3162-1.154.8-Z35 directing against CD86 were 2.52, 5.15 and 0.28 nM respectively.

2.4 Cytokine release of SEB stimulated PBMCs

Anti-CTLA4 antibodies were tested whether they could enhance cytokines release of human PBMC after SEB (from The Second Military Medical University) stimulation. Peripheral blood from healthy donors was obtained and cells were isolated by Ficoll GE Healthcare, 17-1440-02) density gradient centrifugation. After the buoyant layer was removed, the platelets were removed by several washes with medium. A number of 1×10^5 human PBMC cells were added to each well of a 96-well plate. Serial dilutions of test antibodies, positive and negative controls were mixed with SEB (10 ng/mL), and then added to the pelleted cells and incubated for 3 days at 37 °C. The supernatants were collected to measure human IL-2 concentration.

For human IL-2 test, plates were pre-coated with 1.0 μg/ml human IL-2 antibody (R&D System MAB602) at 4 °C for 16-20 hours. After 1 hour blocking with 2% BSA (BovoGen) in DBPS, the supernatants containing IL-2 were added to the plates and incubated at room temperature for 2 hours. After washing three times with PBST (containing 0.05% Tween 20), biotinylated human IL-2 antibody (R&D system, BAF202) was diluted and added at concentration of 0.5 g/mL. The plates were incubated at room temperature for 1 hour. The bound biotinylated antibody was detected by 1:20000 diluted streptavidin conjugated HRP (Invitrogen, SNN1004). After 1 hour incubation, the color was developed by dispensing 100 μL of TMB substrate, and then stopped by 100 μL of 2M HCl. The absorbance at 450 nm and 540 nm was measured using a microplate spectrophotometer.

In a cell-based assay, the humanized antibodies (8.60 nM, 21.4 nM, 53.6 nM, 134 nM, 335 nM) were tested whether they could enhance superantigen SEB stimulated human PBMCs. After 3 days stimulation, IL-2 from the PBMC was measure using ELISA. Compared with an isotype control antibody, both the two humanized antibodies (W3162-1.146.19-Z12,

W3162-1.154.8-Z35) and Ipilimumab could enhance IL-2 release from the PBMCs in a dose-dependent manner (Figure 13).

2.5 Thermostability

The stability of the lead antibodies was tested at different temperature. Briefly, 100 μL each antibody sample was pipetted into individual tubes, and the samples were incubated at 4 °C or 37 °C for 20 hours, or 45 °C or 50 °C for 2 hours. Then the samples were centrifuged at 12,000 rpm for 10 minutes. Those samples were observed to find possible precipitation, and the samples were analyzed by SEC-HPLC for purity and elution time.

The SEC profile of W3162-1.146.19-Z12 at different conditions was shown in Figure 14 a-d. Neither dilution time nor main peak percentage (92.39% to 92.48%) at high temperature conditions significantly changed, comparing with that at low temperature (92.24%). The SEC profile of W3162-1.154.8-Z35 at different high temperature conditions was shown in Figure 14 e-h. Neither dilution time nor main peak percentage (97.14% - 97.17%) significantly changed, compared with at low temperature (96.84%). This set of data indicates that the antibodies were stable in tested high temperature conditions.

2.6 Nonspecific binding

Both FACS and ELISA assays were used to test whether the antibodies binding to other targets. In FACS assay, different cell lines (Ramos, Raji, MDA-MB-453, BT474, Jurkat, Hut78, A431, A204, CaLu-6, A375, HepG2, BxPC-3, HT29, FaDu, 293F, CHO-K1) were adjusted to 1 x 10^5 cells per well. Testing antibodies and Isotype control antibodies were diluted to 10 μg/ml in PBS containing 1%BSA and incubated with cells at 4 °C for 1 hr. The cells were washed twice with 180 μL PBS containing 1%BSA. PE conjugated goat anti-human IgG Fc fragment (Jackson, Catalog number

109-115-098) was diluted to final concentration 5 μg/ml in PBS with 1%BSA, then added to re-suspend cells and incubated at 4 °C in the dark for 30 min. Additional washing steps were performed twice with 180 μL PBS containing 1% BSA followed by centrifugation at 1500 rpm for 4 minutes at 4 °C. Finally, the cells were re-suspended in 100 μL PBS containing 1% BSA and fluorescence values were measured by flow cytometry (BD Canto II) and analyzed by FlowJo.

In the ELISA assay, the testing antibodies, isotype control antibodies were tested binding to 10 different target antigens including Factor VIII, FGFR-ECD, PD-1, CTLA-4.ECD, VEGF, HER3.ECD, OX40.ECD, 4-1BB.ECD, CD22.ECD, CD3e.ECD. A 96-well plate was coated with the individual antigens (2 μg/mL) at 4 °C overnight. After 1 hour blocking with 2% BSA in PBS, wash plate 3 times with 300 μL PBST. Testing antibodies, as well as isotype control antibodies were diluted to 10 μg/mL in PBS containing 2%BSA, then were added to the plate and incubated at room temperature for 2 hours. After 3 times washing with 300 μL PBST, HRP-conjugated goat anti-human IgG antibody (1:5000 diluted in 2%BSA) was added to the plate and incubated at room temperature for 1 hours. Finally, the plates were washed six times with 300 μL PBST. The color was developed by dispensing 100 μL of TMB substrate for 12 min, and then stopped by 100 μL of 2M HCl. The absorbance at 450 nM was measured using a microplate spectrophotometer.

In addition to CTLA-4, other irrelevant proteins were used to test whether the antibody W3162-1.146.19-Z12 and W3162-1.154.8-Z35 were able to bind to these antigens. As shown in Figure 16, among the panel of antigens, only CTLA-4 was detected by the two antibodies. Other antigens did not generate signal in this ELISA assay. On contrast, anti-OX40 antibody did bind to OX40, suggesting this antigen was coated on the plate.

The specificity of the two antibodies were also tested on a panel of different cell lines in FACS assay. The antibodies did not generate detectable signal to any of these cell lines (data not shown).

2.7 In vivo efficacy

Due to antibody W3162-1.146.19-Z12 cross-reacts to both human and murine CTLA-4, the anti-tumor efficacy of this antibody was tested in a syngeneic mouse models. Mouse cancer cell line CT26 was used to establish xenograft mouse model to test anti-CTLA-4 antibody W3162-1.146.19-Z12. An anti-murine CTLA-4 antibody purchased from BioXCell was used as a positive control (BioXCell-BE0131). The tumor cells were maintained in vitro as a monolayer culture in RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin at 37 °C in an atmosphere of 5% CO_2. The tumor cells were routinely subcultured twice weekly after detaching the cells by trypsin-EDTA treatment. The cells growing in an exponential growth phase were harvested and counted for tumor inoculation. Female Balb/C mice were purchased from Beijing Vital River Laboratory Animal Co., Ltd. The mice at age 6-8 weeks with weight approximately 18-22 g were used for the study. Each mouse was inoculated subcutaneously at the right axillaries with 1×10^5 tumor cells in 0.1 mL of PBS mixed with 50 μL matrigel. When the average tumor volume reaches 60-80 mm^3, the animals were randomly grouped. The anti-CTLA-4 antibodies and isotype control were used for treatment: intravenously injected into mice twice a week. The tumor size was measured twice weekly by a vernier caliper, and tumor volume was calculated by the formula $a\times b^2\times\pi/6$ where a is length and b is width (a>b).

When average tumor volume reached approximately 70 mm^3, W3162-1.146.19-Z12 (1 mg/kg, 3 mg/kg, 10 mg/kg) and control antibodies

(10 mg/kg) were injected twice a week for two weeks. The animals were monitored for tumor growth and body weight over time. As shown in Figure 15, W3162-1.146.19-Z12 significantly inhibiting tumor growth in a dose-dependent manner. At 1 mg/kg dose, W3162-1.146.19-Z12 inhibited tumor growth, compared with control group. At 3 mg/kg dose, W3162-1.146.19-Z12 inhibit tumor volume to 160 mm3 at day 19, whereas 10 mg/kg W3162-1.146.19-Z12 induced tumor regression at the end of the study period.

2.8 Epitope mapping

Alanine scanning was used to identify CTLA-4 epitope of the antibodies. In this experiment, alanine residues on hCTLA4 were mutated to glycine residues, and all other residues were mutated to alanines. For each residue of human CTLA4 extracellular domain (ECD), point amino acid substitutions were made using two sequential PCR steps. A pcDNA3.3-hCTLA4_ECD.His plasmid that encodes ECD of human CTLA4 and a C-terminal His-tag was used as template, and a set of mutagenic primers were used for first step PCR using the QuikChange lightning multi site-directed mutagenesis kit (Agilent technologies, Palo Alto, CA). Dpn I endonuclease was used to digest the parental template after mutant strand synthesis reaction. In the second-step PCR, linear DNA expression cassette, composed of a CMV promoter, mutated ECD of CTLA4, a His-tag and a herpes simplex virus thymidine kinase (TK) polyadenylation, was amplified and transiently expressed in HEK293F cells (Life Technologies, Gaithersburg, MD). In addition, three plasmid vectors were constructed to test the epitope of glycans: pcDNA3.3-hCTLA4_ECD.His (N113Q), pcDNA3.3-hCTLA4_ECD.His (N145Q), and pcDNA3.3-hCTLA4_ECD.His (N113Q, N145Q). These three muteins were transiently expressed in HEK293F cells (Life Technologies, Gaithersburg, MD).

In order to test how the mutations affect antibody-binding, a capture ELISA was conducted. Briefly, ipilimumab, W3162-1.146.19-z12 and W3162-1.154.8-z35 (2 μg/mL) monoclonal antibodies were captured by pre-coated with 2 μg/mL goat-anti-human-IgG Fc (Bethyl Laboratories, Montgomery, TX) in plates. After interacting with the supernatant that contains quantified CTLA4 muteins, HRP conjugated anti-His antibody (1:5000 ; Rockland Immunochemicals, Pottstown, PA) was added as detection antibody. TMB was used as substance of HRP. Absorbance was normalized according to the average of control mutants. After setting an additional cutoff to the binding fold change (<0.55), the final determined epitope residues were identified.

The binding activities of antibodies W3162-1.146.19-z12, W3162-1.154.8-z35 and ipilimumab (W316-BMK1) to human CTLA4 were conducted, all three antibodies were found binding to human CTLA4 (Figure 17).

The tested point mutations that affect antibody binding to CTLA-4 was shown in Table 11. According to human CTLA4 crystal structures (PDB code 1AH1), some amino acid residues (e.g. Met38, Val40, Tyr60, Val71, Val73, Arg75, Val84, Cys85, Cys129, Ile149) were unlikely to directly contact any antibodies. The observed binding reductions most probably resulted from the instability or even collapse of CTLA4 structure after alanine substitutions. The final determined epitope residues were listed in Table 12 and marked on Figure 18.

As shown on Figure 18D and E, the epitopes of Ipilimumab and W3162-1.146.19-z12 overlap to each other, except a few residues such as N145 and P138. In comparison, W3162-1.154.8-z35 bound to a smaller area

of CTLA-4 (Figure 18 F) than other two antibodies. All the three antibodies bound to ligand binding domain of CTLA-4 (Figure 18 A and B), which involve the MYPPPY motif.

The overlapped epitopes of Ipilimumab and W3162-1.146.19-z12 did not explain the unique cross-species binding of antibody W3162-1.146.19-z12. As N145 mutation on CTLA-4 only affected W3162-1.146.19-z12 binding to CTLA-4, not affecting other two antibodies, we further looked at the N-glycosylation sites as potential epitopes. The effect of mutations on two glycosylation sites of CTLA4 on antibody-binding activity is shown on Figure 17. The binding of Ipilimumab or W3162-1.154.8-z35 on mutated CTLA-4 was not significantly changed (Figure 17 A and C). In contract, the binding of W3162-1.146.19-z12 on mutated CTLA-4 N145Q significantly reduced whereas this antibody's binding on CTLA-4 with N113Q did not change. This set of data indicates that the glycan (Figure 18E) on N145 of CTLA-4 could be the epitope of W3162-1.146.19-z12. The N145 residue is conserved in CTLA-4 of cynomoguls monkey and mouse.

The description of the present invention has been made above by the examples. However, it is understood by the skilled in the art that the present invention is not limited to the examples. The invention may be embodied in other specific forms without departing form the spirit or essential characteristics thereof. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.

Table 11. The effect of CTLA4 point mutations on antibody binding

Ipilimumab				W3162-1.146.19-z12-IgG1K				W3162-1.154.8-z35-IgG1K			
CTLA4 Residue	position	Fold change [a]	SD	CTLA4 Residue	position	Fold change [a]	SD	CTLA4 Residue	position	Fold change [a]	SD
P	136	0.191	0.00	G	146	0.166	0.00	**P**	136	0.155	0.00
V	40	0.201	0.00	V	40	0.181	0.00	V	40	0.187	0.00
G	146	0.208	0.00	C	129	0.182	0.00	G	146	0.201	0.00
C	129	0.210	0.00	M	38	0.182	0.00	C	129	0.211	0.00
C	85	0.229	0.00	I	149	0.183	0.00	C	85	0.218	0.00
V	84	0.233	0.01	V	81	0.191	0.01	V	84	0.232	0.00
Y	60	0.236	0.04	N*	145	0.196	0.00	M	38	0.238	0.00
M	134	0.240	0.01	Q	76	0.200	0.00	Y	60	0.240	0.07
I	149	0.244	0.01	V	84	0.201	0.00	R	75	0.298	0.00
M	38	0.253	0.02	Y	60	0.223	0.05	I	149	0.319	0.00
V	81	0.268	0.03	**P**	136	0.231	0.00	P	138	0.339	0.00
R	75	0.273	0.00	**M**	134	0.254	0.00	V	71	0.347	0.10
I	143	0.278	0.00	I	128	0.256	0.00	K	65	0.351	0.00
I	128	0.286	0.00	C	85	0.256	0.03	T	88	0.433	0.02
V	71	0.335	0.08	I	143	0.264	0.00	**M**	134	0.455	0.00
K	130	0.364	0.00	R	75	0.278	0.00	E	83	0.479	0.00
G	142	0.369	0.01	V	73	0.338	0.01	V	73	0.498	0.01
G	144	0.375	0.00	V	71	0.343	0.06	R	70	0.515	0.04
T	88	0.377	0.06	K	130	0.348	0.00	A	66	0.519	0.02
R	70	0.378	0.10	A	66	0.395	0.02	L	74	0.520	0.00
V	73	0.380	0.00	L	74	0.398	0.00	**P**	137	0.534	0.00
A	66	0.395	0.03	L	126	0.398	0.02	G	64	0.543	0.10
E	83	0.396	0.02	E	83	0.405	0.01	H	39	0.549	0.01
A	86	0.401	0.03	T	88	0.423	0.06				
P	137	0.407	0.00	P	137	0.425	0.00				
L	74	0.410	0.00	Y	139	0.431	0.00				
L	126	0.412	0.01	T	82	0.436	0.00				
H	39	0.420	0.01	P	138	0.445	0.00				
Y	139	0.434	0.00	E	132	0.457	0.01				
T	82	0.450	0.01	G	144	0.478	0.00				
E	132	0.470	0.04	T	147	0.486	0.03				
M	90	0.479	0.02	L	141	0.486	0.00				
T	147	0.508	0.03	M	90	0.492	0.00				
Y	127	0.508	0.01	Q	148	0.500	0.02				
Q	80	0.517	0.02	V	131	0.504	0.02				
L	141	0.518	0.03	R	70	0.507	0.08				
E	68	0.529	0.00	Y	89	0.512	0.05				
Q	148	0.532	0.04	Y	127	0.529	0.02				
G	125	0.537	0.02	H	39	0.529	0.00				
Q	76	0.545	0.00	T	72	0.541	0.01				
G	92	0.548	0.00	G	142	0.543	0.02				
				C	103	0.544	0.03				

[a] Fold change in binding is relative to the binding of several silent alanine substitutions.

Table 12. Identified epitopes of three antibodies

Ipilimumab			W3162-1.146.19-z12-IgG1K			W3162-1.154.8-z35-IgG1K		
CTLA4 Residue	**Position**	**Location**	**CTLA4 Residue**	**Position**	**Location**	**CTLA4 Residue**	**Position**	**Location**
H	39	A	H	39	A	H	39	A
A	66	B C loop	A	66	B C loop	G	64	B C loop
E	68	C	R	70	C	K	65	B C loop
R	70	C	T	72	C	A	66	B C loop
L	74	C	L	74	C	R	70	C
Q	76	C	Q	76	C	L	74	C
Q	80	C'	V	81	C'	E	83	C'
V	81	C'	T	82	C'	T	88	C'
T	82	C'	E	83	C'	**M**	134	F
E	83	C'	T	88	C'	**P**	136	FG loop
A	86	C'	M	90	C' C'' loop	**P**	137	FG loop
T	88	C'	G	92	C''	**P**	**138**	FG loop
M	90	C' C'' loop	L	126	F	G	146	G
G	92	C''	I	128	F			
G	125	F	K	130	F			
L	126	F	E	132	F			
I	128	F	**M**	134	F			
K	130	F	**P**	136	FG loop			
E	132	F	**P**	137	FG loop			
M	134	F	**P**	**138**	FG loop			
P	136	FG loop	**Y**	139	FG loop			
P	137	FG loop	L	141	G			
Y	139	FG loop	G	142	G			
L	141	G	I	143	G			
G	142	G	G	144	G			
I	143	G	**N**	**145**	G			
G	144	G	G	146	G			
G	146	G	Q	148	G			
Q	148	G						

Claims

1. An antibody or antigen binding fragment thereof, comprising

   a light chain variable region comprising a light chain complementary-determining region 1 (LCDR1) defined by SEQ ID NO: 41, LCDR2 defined by SEQ ID NO: 32, and LCDR3 defined by SEQ ID NO: 22, and

   a heavy chain variable region comprising a heavy chain complementary determining region 1 (HCDR1) defined by SEQ ID NO: 36, HCDR2 defined by SEQ ID NO: 28, and HCDR3 defined by SEQ ID NO: 18; and

   wherein the antibody or the antigen binding fragment specifically binds to CTLA-4.

2. The antibody or an antigen binding fragment thereof according to claim 1, comprising an amino acid sequence that is at least 90% or 95% homologous to SEQ ID NO: 7 or 14.

3. The antibody or antigen binding fragment thereof according to claim 1 or 2, wherein the light chain variable region has the amino acid sequence of SEQ ID NO: 14.

4. The antibody or antigen binding fragment thereof according to any one of claims 1-3, wherein the heavy chain variable region has the amino acid sequence of SEQ ID NO: 7.

5. The antibody or antigen binding fragment thereof according to claim 4, wherein the light chain variable region has the amino acid sequence of SEQ ID NO: 14 and the heavy chain variable region has the amino acid sequence of SEQ ID NO: 7.

6. The antibody or the antigen binding-fragment thereof according to any one of claims 1-5, wherein the antibody inhibits CTLA-4 binding to CD80 or CD86.

7. The antibody or the antigen binding-fragment thereof according to any one of claims 1-6, wherein binding epitope of antibody or antigen binding-fragment comprises N145, polysaccharide on N145, or P138 of CTLA-4.

8. The antibody or an antigen binding fragment thereof according to any one of claims 1-7, wherein the antibody or the antigen binding-fragment
   a) binds to human CTLA-4 with a K_D of 4.77E-10 M or less; and
   b) binds to mouse CTLA-4 with a K_D of l.39E-09 M or less.

9. The antibody or the antigen binding fragment thereof according to any one of claims 1-8, wherein the antibody is chimeric, humanized, fully human, or rat antibody.

10. A nucleic acid molecule encoding the antibody or the antigen binding fragment thereof according to any one of claims 1 to 9.

11. A cloning or expression vector comprising the nucleic acid molecule of claim 10.

12. A host cell comprising one or more expression vectors of claim 11.

13. A process for the production of the antibody of any one of claims 1-9, comprising culturing the host cell of claim 12 and isolating the antibody.

14. A transgenic rat comprising human immunoglobulin heavy and light chain transgenes, wherein the rat expresses the antibody of any one of claims 1-9.

15. A pharmaceutical composition comprising the antibody or the antigen binding fragment thereof according to any one of claims 1 to 9, and one or more of a pharmaceutically acceptable excipient, a diluent and a carrier.

16. An immunoconjugate comprising the antibody or the antigen binding fragment thereof according to any one of claims 1-9, linked to a therapeutic agent.

17. A method for preparing an anti-CTLA-4 antibody or an antigen-binding fragment thereof comprising:

(a) providing:

(i) a heavy chain variable region antibody sequence comprising a CDR1 sequence of SEQ ID NO: 36, a CDR2 sequence of SEQ ID NO: 28; and a CDR3 sequence of SEQ ID NO: 18; and

(ii) a light chain variable region antibody sequence comprising a CDRl sequence of SEQ ID NO: 41, a CDR2 sequence of SEQ ID NO: 32, and a CDR3 sequence of SEQ ID NO: 22; and

(b) expressing the antibody sequence as a protein.

18. The antibody or antigen binding fragment thereof according to any one of claims 1 to 9 for use as a medicament.

19. Use of the antibody or the antigen binding fragment thereof according to any one of claims 1 to 9 in the manufacture of a medicament for the treatment of cancer.

20. Use of the antibody or the antigen binding fragment thereof according to any one of claims 1 to 9 in the manufacture of a medicament for inhibiting growth of tumor cells.

21. The use of claim 20, wherein the tumor cells are of a cancer selected from a group consisting of melanoma, renal cancer, prostate cancer, breast cancer, colon cancer, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, and rectal cancer.